Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial

Introduction and Objective: Mastalgia is defined as painful nodularity for more than 1 week of menstrual cycle. The long list of drugs highlights the ongoing debate about the drug of choice for the management of mastalgia. So in this study, we compared the effectiveness and cost of Centchroman and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S Khadka, S Rajbanshi, S Khaniya, CS Agrawal, S Adhikary
Formato:	article
Lenguaje:	EN
Publicado:	Society of Surgeons of Nepal 2016
Materias:	Centchroman Mastalgia Tamoxifen VAS Surgery RD1-811
Acceso en línea:	https://doaj.org/article/b05a8d76c57742cdaf17e62e6bcbc4df
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b05a8d76c57742cdaf17e62e6bcbc4df
record_format	dspace
spelling	oai:doaj.org-article:b05a8d76c57742cdaf17e62e6bcbc4df2021-12-05T19:16:28ZCentchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial10.3126/jssn.v18i3.153321815-39842392-4772https://doaj.org/article/b05a8d76c57742cdaf17e62e6bcbc4df2016-07-01T00:00:00Zhttps://www.nepjol.info/index.php/JSSN/article/view/15332https://doaj.org/toc/1815-3984https://doaj.org/toc/2392-4772 Introduction and Objective: Mastalgia is defined as painful nodularity for more than 1 week of menstrual cycle. The long list of drugs highlights the ongoing debate about the drug of choice for the management of mastalgia. So in this study, we compared the effectiveness and cost of Centchroman and Tamoxifen in the management of mastalgia. Materials and methods: A total of 106 female patients with the clinical diagnosis of mastalgia were enrolled in the study and randomized to 1:1 ratio into Centchroman and Tamoxifen group for a period of 1 year. The duration of therapy was 3 months. All patients completed the study and follow up. The response of therapy was assessed on 1, 2, 3 and 6 months by using a Visual Analogue Scale (VAS). Results: Baseline mean VAS score was 6.25 in Tamoxifen and 6.49 in Centchroman group.There was marked improvement in VAS score after the treatment in both the groups, which was statistically significant with greater reduction in Centchroman group(p= 0.001).The number of patients who achieved VAS less than 3 were 51(96.2%) in Centchroman and 49(92.5%) in Tamoxifen group at the end of treatment. Tamoxifen was found to be statistically significant and cost-effective (p <0.001) in comparison to Centchroman. Conclusion: We conclude that Centchroman is not inferior to Tamoxifen and both the drugs effectively reduced pain, however Centchroman reduced the pain more than Tamoxifen. S KhadkaS RajbanshiS KhaniyaCS AgrawalS AdhikarySociety of Surgeons of NepalarticleCentchromanMastalgiaTamoxifenVASSurgeryRD1-811ENJournal of Society of Surgeons of Nepal, Vol 18, Iss 3 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Centchroman Mastalgia Tamoxifen VAS Surgery RD1-811
spellingShingle	Centchroman Mastalgia Tamoxifen VAS Surgery RD1-811 S Khadka S Rajbanshi S Khaniya CS Agrawal S Adhikary Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial
description	Introduction and Objective: Mastalgia is defined as painful nodularity for more than 1 week of menstrual cycle. The long list of drugs highlights the ongoing debate about the drug of choice for the management of mastalgia. So in this study, we compared the effectiveness and cost of Centchroman and Tamoxifen in the management of mastalgia. Materials and methods: A total of 106 female patients with the clinical diagnosis of mastalgia were enrolled in the study and randomized to 1:1 ratio into Centchroman and Tamoxifen group for a period of 1 year. The duration of therapy was 3 months. All patients completed the study and follow up. The response of therapy was assessed on 1, 2, 3 and 6 months by using a Visual Analogue Scale (VAS). Results: Baseline mean VAS score was 6.25 in Tamoxifen and 6.49 in Centchroman group.There was marked improvement in VAS score after the treatment in both the groups, which was statistically significant with greater reduction in Centchroman group(p= 0.001).The number of patients who achieved VAS less than 3 were 51(96.2%) in Centchroman and 49(92.5%) in Tamoxifen group at the end of treatment. Tamoxifen was found to be statistically significant and cost-effective (p <0.001) in comparison to Centchroman. Conclusion: We conclude that Centchroman is not inferior to Tamoxifen and both the drugs effectively reduced pain, however Centchroman reduced the pain more than Tamoxifen.
format	article
author	S Khadka S Rajbanshi S Khaniya CS Agrawal S Adhikary
author_facet	S Khadka S Rajbanshi S Khaniya CS Agrawal S Adhikary
author_sort	S Khadka
title	Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial
title_short	Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial
title_full	Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial
title_fullStr	Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial
title_full_unstemmed	Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial
title_sort	centchroman versus tamoxifen in the management of mastalgia: a randomized controlled clinical trial
publisher	Society of Surgeons of Nepal
publishDate	2016
url	https://doaj.org/article/b05a8d76c57742cdaf17e62e6bcbc4df
work_keys_str_mv	AT skhadka centchromanversustamoxifeninthemanagementofmastalgiaarandomizedcontrolledclinicaltrial AT srajbanshi centchromanversustamoxifeninthemanagementofmastalgiaarandomizedcontrolledclinicaltrial AT skhaniya centchromanversustamoxifeninthemanagementofmastalgiaarandomizedcontrolledclinicaltrial AT csagrawal centchromanversustamoxifeninthemanagementofmastalgiaarandomizedcontrolledclinicaltrial AT sadhikary centchromanversustamoxifeninthemanagementofmastalgiaarandomizedcontrolledclinicaltrial
_version_	1718371086158004224

Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial

Ejemplares similares